|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Strong associations with CBC were found for carrying a BRCA1 (RR = 3.7; 95%CI:2.8-4.9), BRCA2 (RR = 2.8; 95%CI:1.8-4.3) or CHEK2 c.1100delC (RR = 2.7; 95%CI:2.0-3.7) mutation.
|
30580169 |
2019 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriers of BRCA1 and BRCA2 mutations have an increased risk of contralateral breast cancer and cancer of the ovary.
|
15952973 |
2005 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with BRCA1-associated breast cancer had twice as many progesterone-receptor-negative tumours (p<0.005) and development of contralateral breast cancer was four to five times as frequent as in the sporadic group (p<0.001).
|
9652611 |
1998 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
ER-status of the first breast cancer was predictive of ER-status of asynchronous contralateral breast cancer (P = 0.0004 for BRCA1; P = 0.002 for BRCA2).
|
22144499 |
2012 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis.
|
26239694 |
2015 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations of the BRCA1 or BRCA2 genes have been shown to strongly predispose towards the development of contralateral breast cancer in patients from large multi-case families.
|
11556836 |
2001 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The incidence rate of contralateral breast cancer in BRCA1/2 mutation carriers was 0.99%/year.
|
29176636 |
2018 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumour size (hazard ratio (HR) 1.02 per mm increase, P = 0.016) and node status (HR 2.6 for three or more involved nodes versus node negative, P = 0.017) were independent predictors of overall survival in the familial non-BRCA1/2 group, and in the whole group, whereas contralateral breast cancer (HR 0.7, P = 0.503) and risk-reducing contralateral mastectomy (HR 0.4, P = 0.163) were not.
|
16758466 |
2006 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Notably, women with ER-/PR- first tumors were more likely to develop CBC with the ER-/PR- phenotype (RR = 5.4, 95% CI 3.0-9.5), and risk remained elevated in multiple subgroups: BRCA1/2 mutation non-carriers, women younger than 45 years of age, women without a breast cancer family history, and women who were not treated with tamoxifen.
|
28724391 |
2017 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study.
|
19597986 |
2010 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Contralateral prophylactic mastectomy (CPM) reduces the risk of contralateral breast cancer (BC) following unilateral BC, but may not increase survival in BRCA1/2 mutation negative women.
|
27969575 |
2017 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The rate of contralateral breast cancer was significantly increased in all patients with a family history: BRCA1/2 carriers versus controls (p=0.0003), non-carriers versus controls (p=0.0034) and carriers versus non-carriers (p=0.02).
|
16140006 |
2005 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRCA1 mutation carriers had a significantly earlier age of diagnosis than non-carriers (p = 0.0001) and more frequently developed contralateral breast cancer (p = 0.04).
|
10817354 |
2000 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, contralateral prophylactic mastectomy (CPM) significantly decreased contralateral breast cancer incidence in BRCA1/2 mutation carriers (RR, 0.072; 95% CI, 0.035-0.148).
|
26979395 |
2016 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The average cumulative risks by age 70 years for BRCA1 carriers were estimated to be 60% (95% confidence interval [CI] = 44% to 75%) for breast cancer, 59% (95% CI = 43% to 76%) for ovarian cancer, and 83% (95% CI = 69% to 94%) for contralateral breast cancer.
|
23628597 |
2013 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conditional logistic regression was used to compare the risk of CBC associated with chemotherapy and tamoxifen in BRCA1/BRCA2 mutation carriers and non-carriers.
|
20135344 |
2010 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent studies indicate that high-risk breast cancer patients (ie, women who carry mutations in BRCA1/2 genes) who opt for contralateral prophylactic mastectomy (CPM) have a substantially reduced risk of developing contralateral breast cancer.
|
17159191 |
2007 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The 15-year actuarial risk of contralateral breast cancer was 36.1% for women with a BRCA1 mutation and was 28.5% for women with a BRCA2 mutation.
|
21487411 |
2011 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After 25 years, 62.9% (95% CI, 50.4% to 75.4%) of patients with BRCA1 mutation who were younger than 40 years of age at first breast cancer developed contralateral breast cancer, compared with only 19.6% (95% CI, 5.3% to 33.9%) of those who were older than 50 years of age at first breast cancer.
|
19858402 |
2009 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, we conducted a prospective study of the relationship between oophorectomy and the risk of contralateral breast cancer in 1781 BRCA1 and 503 BRCA2 mutation carriers with breast cancer.
|
30756284 |
2019 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we evaluated the association between these factors and CBC risk among BRCA1 and BRCA2 (BRCA1/2) mutation carriers and non-carriers.
|
20130978 |
2010 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Women with BRCA1- or BRCA2-associated breast cancer are at increased risk for contralateral breast cancer and ovarian cancer and therefore may consider secondary cancer prevention strategies, such as prophylactic surgery and tamoxifen therapy.
|
10665701 |
2000 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tamoxifen protected against contralateral breast cancer for carriers of BRCA1 mutations (odds ratio 0.38, 95% CI 0.19-0.74) and for those with BRCA2 mutations (0.63, 0.20-1.50).
|
11130383 |
2000 |
|
Contralateral breast cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Women diagnosed with breast cancer who carry pathogenic variants in genes with proven associations with breast cancer (BRCA1/2) or highly likely associations (PTEN, PALB2) require additional risk assessment to facilitate treatment decisions that will limit in-breast tumor recurrence and contralateral breast cancer.
|
27401444 |
2016 |
|
Contralateral breast cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This may explain the effectiveness of tamoxifen in preventing contralateral breast cancer development in BRCA1 mutation carriers.
|
18405391 |
2008 |